Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis

Psoriasis

Real-world treatment patterns in patients with generalized pustular psoriasis (GPP)

J Am Acad Dermatol

Strober B, Kwiatkowski H, Lavasani L, Semeco J, Lakshminarasimhan B, Lebwohl M, Gottlieb AB

doi: 10.1016/j.jaad.2025.08.089

PsoriasisPsoriatic ArthritisFurther Publications Rheumatology

Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022-2023

Adv Ther

Puig L, Sewerin P, Schuster C, Ng KJ, Papadimitropoulos M, Gadagamma S, Nuñez M, Lampropoulou A

doi: 10.1007/s12325-025-03258-9

Psoriasis

Sex Disparities of Health-related Quality of Life in Moderate to Severe Psoriasis: A Real-world Analysis from the Swiss Psoriasis Registry (SDNTT)

Acta Derm Venereol

Lichtenberger R, Maul LV, Birkenmaier I, Oyanguren I, Ak M, Heidemeyer K, Schlapbach C, Yawalkar N, Egeberg A, Thomsen SF, Thyssen JP, Sorbe C, Boehncke WH, Conrad C, Cozzio A, Kokolakis G, Micheroli R, Wu JJ, Kündig T, Navarini A, Maul JT

doi: 10.2340/actadv.v105.42296

Further Publications Dermatology

Hidradenitis suppurativa with and without draining tunnels: A real-world study characterizing differences in treatment and disease burden

J Eur Acad Dermatol Venereol

Ingram JR, Marzano AV, Prens E, Schneider-Burrus S, Warren RB, Keal A, Jha R, Hernandez Daly AC, Kimball AB

doi: 10.1111/jdv.20550

Psoriatic Arthritis

Psoriatic arthritis phenotype clusters and their association with treatment response: a real-world longitudinal cohort study from the psoriatic arthritis research consortium

Ann Rheum Dis

Karmacharya P, Crofford LJ, Byrne DW, Stephens-Shields A, Husni ME, Scher JU, Craig E, Fitzsimmons R, Reddy SM, Magrey MN, Walsh JA, Ogdie A

doi: 10.1136/ard-2024-226150

Psoriatic Arthritis

Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors

Adv Ther

Mease PJ, Walsh JA, Fitzgerald TP, Chakravarty SD, Adamson E, Emond B, Rossi C, Schwartzbein S, Yokoji K, Wang Y, Lefebvre P, Pilon D, Singla S, Merola JF

doi: 10.1007/s12325-025-03416-z

Psoriatic Arthritis

Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors

Adv Ther

Mease PJ, Ferrante SA, Shiff NJ, Fitzgerald TP, Chakravarty SD, Walsh JA

doi: 10.1007/s12325-024-03042-1

Rheumatoid Arthritis

Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study

Arthritis Res Ther

Östör A, Feist E, Sidiropoulos P, Avouac J, Rebella M, Namas R, McDearmon-Blondell E, Gao T, Lagunes-Galindo I, Strengholt S, Zisman D, Attar S

doi: 10.1186/s13075-025-03528-5

Psoriatic Arthritis

Real-world evidence on palmoplantar pustulosis: Patient characteristics, diagnostic challenges and predictive factors for treatment survival - a retrospective registry study

Br J Dermatol

Graier T, Bordag N, Weger W, Laschober N, Ratzinger G, Jonak C, Prillinger K, Müllegger R, Mlynek A, Lange-Asschenfeldt B, Häring N, Hoetzenecker W, Posch C, Ellersdorfer C, Sator P, Gruber B, Hofer A, Gruber-Wackernagel A, Legat FJ, Großschädl K, Gruber V, Schadelbauer E, Repelnig M, Gressenberger P, Widnig A, Falkensteiner K, Salmhofer W, Wolf P

doi: 10.1093/bjd/ljaf394

Related content

Real-world treatment patterns in patients with generalized pustular psoriasis (GPP)

Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022-2023

Sex Disparities of Health-related Quality of Life in Moderate to Severe Psoriasis: A Real-world Analysis from the Swiss Psoriasis Registry (SDNTT)

Hidradenitis suppurativa with and without draining tunnels: A real-world study characterizing differences in treatment and disease burden

Psoriatic arthritis phenotype clusters and their association with treatment response: a real-world longitudinal cohort study from the psoriatic arthritis research consortium

Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors

Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors

Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study

Real-world evidence on palmoplantar pustulosis: Patient characteristics, diagnostic challenges and predictive factors for treatment survival - a retrospective registry study